摘要
目的探究甘露特钠胶囊治疗卒中后认知障碍的临床疗效。方法选取2021年01月-2022年08月住院的24例卒中后认知障碍患者为研究对象,据随机数字表分为观察组、对照组,每组各12例。两组总疗程均为3月。通过比较两组患者简易智力状态检查量表(MMSE)、蒙特利尔认知评估量表(MoCA)、日常生活自理能力(ADL)评估临床疗效,并观察治疗过程中出现的不良反应,评估治疗安全性。结果比较治疗前两组的MMSE及其分项(定向力、记忆力、计算力、回忆能力、语言能力)、MoCA及其分项(空间执行功能、注意力、语言能力、抽象、延迟回忆、定向力)、ADL,差异均无统计学意义(P>0.05)。两组治疗后MMSE全部分项和MoCA分项中的空间执行、抽象、延迟回忆、定向力有统计学差异(P<0.05),两组治疗后MoCA分项注意力、语言能力无统计学差异(P>0.05)。治疗前两组MoCA中命名有统计学差异(P<0.05),但是治疗后命名无统计学差异(P>0.05)。两组出现不良反应的例数分别为3例、2例,差异无统计学意义(P>0.05)。结论甘露特钠胶囊治疗卒中后认知障碍患者具有显著的临床效果,且与常规治疗安全性相当,因此甘露特钠胶囊治疗卒中后认知障碍的治疗方式值得推广。
Objective To explore the clinical efficacy of sodium oligomannate for post-stroke cognitive impairment.Methods 24 patients with post-stroke cognitive impairment hospitalized in Zhengzhou Central Hospital Affiliated to Zhengzhou University from January 2021 to August 2022 were selected as the research objects.According to the random number table,the observation group,the control group,with 12 patients in each group.The total course of treatment in both groups was 3 months.The clinical efficacy was evaluated by comparing Mini-mental State Examination(MMSE),Montreal Cognitive Assessment(MoCA)and ability of daily living(ADL)between the two groups,and the adverse reactions during treatment were observed to evaluate the safety of treatment.Results MMSE and its sub-items(orientation,memory,calculation,recall,language ability),MoCA and its sub-items(spatial executive function,attention,language ability,abstraction,delayed recall,orientation)and ADL were compared between the two groups before treatment,and there was no significant difference(P>0.05).After treatment,there were statistical differences in spatial execution,abstraction,delayed recall and orientation between the two groups in all MMSE items and MoCA items(P<0.05),but there were no statistical differences in attention and language ability of MoCA items between the two groups(P>0.05).There was statistical difference in the naming of MoCA between the two groups before treatment(P<0.05),but no statistical difference in naming after treatment(P>0.05).The number of adverse reactions in the two groups was 3 and 2,respectively,with no statistical significance(P>0.05).Conclusions Sodium oligomannate has a significant clinical effect in the treatment of patients with post-stroke cognitive impairment,and the safety is comparable to that of conventional treatment.Therefore,sodium oligomannate is worth promoting in the treatment of post-stroke cognitive impairment.
作者
吴孟娇
王景信
邵芃
龚新靖
马秀娟
刘碧原
何鹤
田小雨
WU Mengjiao;WANG Jingxin;SHAO Peng(Department of Rehabilitation Medicine,Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,China)
出处
《航空航天医学杂志》
2023年第6期654-657,共4页
Journal of Aerospace medicine
